Përdorimi i qelizave car-t në pacientët me hemopati malinje (Review).

Autori

  • Agim Koçiraj

DOI:

https://doi.org/10.55312/op.v14i2.4730

Abstract

Të shpjegojë thelbin e terapise CAR-T dhe efektivitetin e saj në trajtimin e pacientëve me sëmundje malinje të gjakut.

Parole chiave:

Receptori Antigenik Kimerik – T (CAR-limfocitet T)., Terapia imunoqelizore autologe,, Antigeni B-limfocitar CD19 (CD19),, Diffuse Large B Cell Lymphoma (DLBCL), limfocitet T, Limfocitet B,, US Food and Drugs Administration (FDA), US Food and Drugs Administration (FDA),, European Medical Agency (EMA),, imfoma Jo-Hodgkiniane me Qeliza B (NHL),, leukemia akute limfoblastike B (ALL), provat klinike.

Downloads

I dati di download non sono ancora disponibili.

Riferimenti bibliografici

  1. C.H. June, et al. CAR T cell immunotherapy for human cancer. Science 2018;359(6382):1361-5;doi:10.1126/science.aar6711.

  2. Salyka Sengsayadeth; Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175669/

  3. Chimeric agent receptor (CAR) T-Cell therapy. CancerFAx. 2020.https://cancerfax.com/car-t-cell-therapy/.

  4. FDA approval brings first gene therapy to the United States. U.S. Food Drugs Adm. (2017). https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-unitedstates

  5. FDA Approves Second CAR T-cell Therapy. Cancer Discov.;8(1):5-6. doi:10.1158/2159-8290.CDNB2017-155;

  6. First two CAR-T cells medicines recommended for approval in the European Medicine Agency. 2017.https://www.ema.europa.eu/en/documents/press-release/first-two-car-t-cells-medicines

  7. Massimo Fusconi, Andrea Gallo, Armando De Virgilio, Stefania Nataliz. B Lymphocyte Subsets in Patients with Rhinoscleroma. Otolaryngology Head and Neck Surgery 144(5):809-14, February 2011,DOI:10.1177/0194599810396134, Source PubMed

  8. Alaa Alnefaie, Sarah Albogami, Yousif Asiri, Tanveer Ahmad, Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.

  9. R.K. Iyer, et al. Industrializing Autologous Adoptive Immunotherapies: Manufacturing Advances and Challenges. Front Med (Lausanne). 2018;5:150;doi: 10.3389/fmed.2018.00150. eCollection 2018.

  10. E.S. Allen, et al. Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion. 2017;57(5):1133-41;doi: 10.1111/trf.14003. Frontiers in Bioengineering and Biotechnology. 22 June 2022.https://www.frontiersin.org/articles/10.3389/fbioe.2022.797440/full

  11. Stephen J. Schuster, M.D; Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://www.nejm.org/doi/full/10.1056/nejmoa1804980.

  12. Jeremy S Abramson; Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. https://www.thelancet.com/article/S0140-6736(20)31366-0/fulltext

  13. Emily Whitehead foundation https://emilywhiteheadfoundation.org/news/celebrating-10-years-cancer-free/

Downloads

Pubblicato

2024-06-06

Come citare

Koçiraj, A. (2024). Përdorimi i qelizave car-t në pacientët me hemopati malinje (Review). Optime, 14(2), 11–20. https://doi.org/10.55312/op.v14i2.4730

Fascicolo

N. 2 (2022): Optime

Sezione

Artikuj